Prostate Cancer (Adenocarcinoma)
85
43
46
13
Key Insights
Highlights
Success Rate
81% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
3.5%
3 terminated out of 85 trials
81.3%
-5.3% vs benchmark
6%
5 trials in Phase 3/4
15%
2 of 13 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 13 completed trials
Clinical Trials (85)
Development of an Intraoperative Adaptive Biopsy System for Prostate Cancer: Integrating Imaging Navigation With Metabolic Feedback for Dynamic Decision-Making
A Single-Arm, Blinded, Fluorescent PSMA Histopathology Trial of AS1986NS
Molecular Imaging Informed Radiation Dose Escalation to Sites of Recurrent Disease and De-escalation to Uninvolved Areas in Salvage Radiotherapy Using SBRT for Prostate Cancer to Reduce Treatment Toxicity
Micro-ultrasound-Guided Focal Laser Ablation for Intermediate-Risk Prostate Cancer: Safety & Effectiveness
Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer
A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec
Spatial Multi-Omics of Perineural Invasion Microenvironment and Prognosis in Prostate Cancer
Intratumoral Microbiota and Immune Microenvironment in Prostate Cancer
ProA Study: ProActive Management Model in Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Treated by Apalutamide
Phase I Study of Docetaxel and 177-Lutetium-PSMA-I&T in First-Line Treatment for Patients With Metastatic Castration-Resistant Prostate Adenocarcinoma
Study of Oral MRT-2359 With Apalutamide in Prostate Cancer
RegisterPROS - A Registry for Prostate Cancers
A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate or Darolutamide
Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy
68Ga-PSMA-11 PET/MRI for Selecting Men With Prostate Cancer for Focal Therapy
PRO-BOOST-LC: Whole-Gland Boost Strategies Versus SBRT Monotherapy in PSMA-Staged Localized and Locally Advanced Prostate Cancer
REDI-CaP(Recovery of Erectile Dysfunction Induced in Prostate Cancer Patients)
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
Pilot Feasibility Study of a Dyadic Culinary Nutrition Intervention
Evaluation of Pelvic Floor Function and Psychosocial Sequelae Following Radical Prostatectomy for Prostate Cancer